Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131350 | 0.91 | KMT2A (0.47) | KMT2AMEN1MAPK14CNR2MCHR1 | |
| SCHEMBL4141827 | 0.87 | HRH3 (0.49) | KMT2AMAPK14MCHR1HRH3KCNH2 | |
| SCHEMBL4132197 | 0.85 | HRH3 (0.53) | MCHR1HRH3KCNH2 | |
| SCHEMBL4135448 | 0.85 | LMNA (0.45) | KMT2AMAPK14MCHR1HRH3NAMPT | |
| SCHEMBL4132414 | 0.81 | HRH3 (0.45) | KMT2AMEN1HRH3 | |
| SCHEMBL4144854 | 0.81 | HRH3 (0.52) | KMT2AMEN1HRH3KCNH2HTR1A | |
| SCHEMBL4136102 | 0.80 | FAAH (0.44) | MCHR1 | |
| SCHEMBL4143084 | 0.78 | KCNH2 (0.47) | MCHR1HRH3KCNH2HSD17B10HTR1A | |
| SCHEMBL4144841 | 0.78 | KCNH2 (0.48) | KMT2AMEN1MAPK14HRH3KCNH2 | |
| SCHEMBL4135538 | 0.77 | L3MBTL3 (0.53) | KMT2AMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | KMT2A 1670/4885MEN1 3359/4885MAPK14 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.